Theranexus SA (FR:ALTHX) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Theranexus, in collaboration with the Beyond Batten Disease Foundation, has announced promising phase I/II trial results for Batten-1 in treating Batten disease CLN3, showing potential in stabilizing visual acuity. These findings, presented at the Child Neurology Society Annual Meeting, support the advancement to a phase III trial, with visual acuity as the primary endpoint. The company is exploring options to fund the next trial phase, highlighting its commitment to advancing treatment for this rare disease.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.